Posts filed under ‘Meta-Análisis’

Comparison Between Carbapenems and β-Lactam/β-Lactamase Inhibitors in the Treatment for Bloodstream Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: A Systematic Review and Meta-Analysis

Open Forum Infectious Diseases April 2017 V.4 N.2

Maged Muhammed; Myrto Eleni Flokas; Marios Detsis; Michail Alevizakos; Eleftherios Mylonakis

Background.

Carbapenems are widely used for the management of bloodstream infections (BSIs) caused by extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE). However, the wide use of carbapenems has been associated with carbapenem-resistant Enterobacteriaceae development.

Methods.

We searched the PubMed and Scopus databases (last search date was on June 1, 2016) looking for studies that reported mortality in adult patients with ESBL-PE BSIs that were treated with carbapenems or β-lactam/β-lactamase inhibitors (BL/BLIs).

Results.

Fourteen studies reported mortality data in adult patients with ESBL-PE BSI that were treated with carbapenems or BL/BLIs. Among them, 13 studies reported extractable data on empiric therapy, with no statistically significant difference in mortality of patients with ESBL-PE BSI that were treated empirically with carbapenems (22.1%; 121 of 547), compared with those that received empiric BL/BLIs (20.5%; 109 of 531; relative risk [RR], 1.05; 95% confidence interval [CI], 0.83–1.37; I2 = 20.7%; P = .241). In addition, 7 studies reported data on definitive therapy. In total, 767 patients (79.3%) received carbapenems and 199 patients (20.6%) received BL/BLIs as definitive therapy, and there was again no statistically significant difference (RR, 0.62; 95% CI, 0.25–1.52; I2 = 84.6%; P < .001). Regarding specific pathogens, the use of empiric BL/BLIs in patients with BSI due to ESBL-Escherichia coli was not associated with a statistically significant difference in mortality (RR, 1.014; 95% CI, 0.491–2.095; I2 = 62.5%; P = .046), compared with the use of empiric carbapenems.

Conclusions.

These data do not support the wide use of carbapenems as empiric therapy, and BL/BLIs might be effective agents for initial/empiric therapy for patients with BSI caused by likely ESBL-PE, and especially ESBL-E coli.

PDF

https://watermark.silverchair.com/api/watermark?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAc8wggHLBgkqhkiG9w0BBwagggG8MIIBuAIBADCCAbEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQM5BUXSGMYAIN3BE1LAgEQgIIBgqYDSmwh2K3TlymgVZZt0vquuMz0auSmoQ71OT_r9GA6JxA5dMpUtlTojUXLhC28lojPv7HxfS47oBD9v2qsjEy2p-YKFemlWrwcVp4a0v99qMl6D4nzA-0WlQGOA8o89kr97soTVbSLC–nilk62R1koE5p7oZ9D_ISiuLzN2kAUCBvoxQyTMdE_byt2eEzK1r1HXrv7Fe8FmERbpAk_at7HXqOJhvZcC5xz2cOGfJV1-oNl4n2d74O2hQfdokHRlPu8EbPx_L2t8kwDaES7f7bBzT52cQi-jvuBr7a9OQwBEpUWzMOyB03zwoqpls1eIYxsh_m67d9gyQherNT3E0cEKNAEb5K49VZLMhAxTv33722rS1o_jeIUi_Chv1ndbM0itD725XwvoUADC7ner73YqpCb7l8MXlJYcLhmm_ikYkppJWs6jVyyN4cx8ueRN3pW2UqcVW4AX6WKz_na2W0xPt6IQB55hUMflu_B10duTKe2j30Ae3vV__Uqef9GfVl

Advertisements

September 3, 2017 at 6:57 pm

Association Between Cytomegalovirus Reactivation and Clinical Outcomes in Immunocompetent Critically Ill Patients: A Systematic Review and Meta-Analysis

Open Forum Infectious Diseases April 2017 V.4 N.2

Philippe Lachance; Justin Chen; Robin Featherstone; Wendy I. Sligl

Background.

The aim of our systematic review was to investigate the association between cytomegalovirus (CMV) reactivation and outcomes in immunocompetent critically ill patients.

Methods.

We searched electronic databases and gray literature for original studies and abstracts published between 1990 and October 2016. The review was limited to studies including critically ill immunocompetent patients. Cytomegalovirus reactivation was defined as positive polymerase chain reaction, pp65 antigenemia, or viral culture from blood or bronchoalveolar lavage. Selected patient-centered outcomes included mortality, duration of mechanical ventilation, need for renal replacement therapy (RRT), and nosocomial infections. Health resource utilization outcomes included intensive care unit and hospital lengths of stay.

Results.

Twenty-two studies were included. In our primary analysis, CMV reactivation was associated with increased ICU mortality (odds ratio [OR], 2.55; 95% confidence interval [CI], 1.87–3.47), overall mortality (OR, 2.02; 95% CI, 1.60–2.56), duration of mechanical ventilation (mean difference 6.60 days; 95% CI, 3.09–10.12), nosocomial infections (OR, 3.20; 95% CI, 2.05–4.98), need for RRT (OR, 2.37; 95% CI, 1.31–4.31), and ICU length of stay (mean difference 8.18 days; 95% CI, 6.14–10.22). In addition, numerous sensitivity analyses were performed.

Conclusions.

In this meta-analysis, CMV reactivation was associated with worse clinical outcomes and greater health resource utilization in critically ill patients. However, it remains unclear whether CMV reactivation plays a causal role or if it is a surrogate for more severe illness.

PDF

https://watermark.silverchair.com/api/watermark?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAdcwggHTBgkqhkiG9w0BBwagggHEMIIBwAIBADCCAbkGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMgS29QRsi_OI3SkaMAgEQgIIBigRs9nl2ylsVhYS_sYzV1Exhw5kNEVc_CDMHi9al85en5nmbiM0fSguSAPaX7eVjsRODgkAPeEpkpHFXtT5ee2umJp97CEvGaAbkiVReIdzG4W2RNfMvE2sN1dsphR2nXEn42SJyigJqE4fzz8cIaXZ_D-EACpZzDmIRmUo86ZcUsycSI2PzFbJFj19cTvvoID75bRPJGugrZ8SAfBf6V6-1IrrVl8xG1P7LAmi8eED3QPkcOjtAWOyzyW8WPYJ_5JOJPPAUzlNTmWAKP_9QjSg3NBavgOdzFrhwpzWnF7DYh5qVYp2bg2jrG3iXICmUVNPuC32npr3L2qEWvfmA4-_gQfRgRLvm8G42pCbdO1bBp5NGgHoMFnGHIlF3s-z4Xx7as7oIryKBJsd-MG9CE5kkL9d_x6nJLEr-WqRPZF6rmWl_0VWYfbOyAIn7u3OJrtX9NrLBsFWsmCxKa7Ghsvbvfkk9jpoerEn8x48ljyevLRq7bimX0gm-Vgo3GtltcVdajTLQ5-rUsEQ

September 3, 2017 at 6:43 pm

Distribution of Fatal Vibrio Vulnificus Necrotizing Skin and Soft-Tissue Infections: A Systematic Review and Meta-Analysis.

Medicine (Baltimore). 2016 Feb;95(5):e2627.

Huang KC1, Weng HH, Yang TY, Chang TS, Huang TW, Lee MS.

Author information

1 From the College of Medicine, Chang Gung University, Taoyuan (K-CH, H-HW, T-SC, T-WH, MSL); Department of Orthopaedic Surgery (K-CH, T-YY, T-WH); Department of Diagnostic Radiology (H-HW); Department of Gastroenterology, Chang Gung Memorial Hospital, Chaiyi (T-SC); and Department of Orthopaedic Surgery, Chang Gung Memorial Hospital, Kaohsiung, Taiwan (MSL).

Abstract

Vibrio vulnificus necrotizing skin and soft tissue infections (VNSSTIs), which have increased significantly over the past few decades, are still highly lethal and disabling diseases despite advancing antibiotic and infection control practices. We, therefore, examined the spatiotemporal distribution of worldwide reported episodes and associated mortality rates of VNSSTIs between 1966 and 2014. The PubMed and Cochrane Library databases were systematically searched for observational studies on patients with VNSSTIs. The primary outcome was all-cause mortality. We did random-effects meta-analysis to obtain estimates for primary outcomes; the estimates are presented as means plus a 95% confidence interval (CI). Data from the selected studies were also extracted and pooled for correlation analyses.Nineteen studies of 2227 total patients with VNSSTIs were analyzed. More than 95% of the episodes occurred in the subtropical western Pacific and Atlantic coastal regions of the northern hemisphere. While the number of cases and the number of deaths were not correlated with the study period (rs = 0.476 and 0.310, P = 0.233 and 0.456, respectively), the 5-year mortality rate was significantly negatively correlated with them (rs = -0.905, P = 0.002). Even so, the pooled estimate of total mortality rates from the random-effects meta-analysis was as high as 37.2% (95% CI: 0.265-0.479).These data suggest that VNSSTIs are always an important public health problem and will become more critical and urgent because of global warming. Knowing the current distribution of VNSSTIs will help focus education, policy measures, early clinical diagnosis, and appropriate medical and surgical treatment for them.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4748892/pdf/medi-95-e2627.pdf

August 18, 2017 at 3:51 pm

Systematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?

Front Pharmacol. 2016 Sep 23;7:330. eCollection 2016.

Chuan J1, Zhang Y1, He X1, Zhu Y1, Zhong L1, Yu D1, Xiao H1.

Author information

1 Department of Pharmacy, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of China Chengdu, China.

Abstract

Objective: Telavancin is approved to treat complicated skin and skin structure infections, hospital-acquired, and ventilator-associated bacterial pneumonia caused by Staphylococcus aureus. A previous meta-analysis of randomized controlled trials suggested that it might be an alternative to vancomycin in cases of difficult-to-treat meticillin-resistant S. aureus infections. We did a meta-analysis including one new trial to access the efficacy and safety of telavancin.

Methods: We searched PubMed, Cochrane Central Register of Controlled Trials, EMBASE and ClinicalTrials.gov up to December 30, 2015 to identify randomized controlled trials that assessed the clinical efficacy, eradication efficiency, adverse events and laboratory abnormalities of telavancin vs. other antibiotic agents for bacterial infection. Meta-analysis was performed using Review Manager 5.3.0.

Results: Five studies (3790 participants) were included in the meta-analysis. There was no significant difference in treatment success with telavancin than with control antibiotic agents. The pooled pathogen eradication for the telavancin group was numerically higher than that for the control groups, but there was no significant difference. While all-cause mortalities and serious adverse events were comparable between telavancin and control antibiotic agents, adverse event-related withdrawals (OR 1.47, 95% CI 1.13-1.91) were higher in telavancin group. The total number adverse events were more in the telavancin group than in the control groups, especially in the digestive system (OR 1.57, 95% CI 1.37-1.79), nervous system (OR 2.14, 95% CI 1.86-2.47) and urogenital system (OR 2.54, 95% CI 1.99-3.25). Serum creatinine increase (OR 2.25, 95% Cl 1.78-2.85) and hypokalemia (OR 1.74, 95% CI 1.19-2.53) occurred more frequently in telavancin group compared to control groups.

Conclusion: Telavancin may be as effective as but no better than the comparison therapy for S. aureus infection. However, because of the high risk of adverse event-related withdrawals and potential nephrotoxicity, prudence with the clinical use of telavancin in infections is required.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033967/pdf/fphar-07-00330.pdf

August 1, 2017 at 9:10 pm

Timing of preoperative antibiotic prophylaxis in 54,552 patients and the risk of surgical site infection: A systematic review and meta-analysis

Medicine July 2017 V.96 N.29 P.e6903

de Jonge, Stijn Willem MDa; Gans, Sarah L. MD, PhDa; Atema, Jasper J. MD, PhDa; Solomkin, Joseph S. MDb; Dellinger, Patchen E. MDc; Boermeester, Marja A. MD, PhDa,*

Abstract

The aim of the study was to assess the effect of timing of preoperative surgical antibiotic prophylaxis (SAP) on surgical site infection (SSI) and compare the different timing intervals.

The benefit of routine use of SAP prior to surgery has long been recognized. However, the optimal timing has not been defined. For the purpose of developing recommendations for the World Health Organization guideline for SSI prevention, a systematic review and meta-analysis of all relevant evidence was conducted.

Major medical databases were searched from 1990 to 2016. The primary outcome was SSI after preoperative-SAP comparing different timing intervals. Adjusted odds ratios (OR) with 95% confidence intervals (CI) were extracted and pooled for each comparison with a random effects model.

Fourteen papers with 54,552 patients were included in this review. In a quantitative analysis, there was no significant difference when SAP was administered 120–60 minutes prior to incision compared to administration 60–0 minutes prior to incision. Studies investigating different timing intervals within the last 60 minutes time frame reported contradictive results. The risk of SSI almost doubled when SAP was administered after first incision (OR:1.89; 95%CI:[1.05–3.40]) and was 5 times higher when administered more than 120 minutes prior to incision (OR5.26; 95%CI:[3.29–8.39]).

Administration of antibiotic prophylaxis more than 120 minutes before incision or after incision is associated a higher risk of surgical site infections than administration less than 120 minutes before incision. Within this 120-minute time frame prior to incision, no differential effects could be identified. The broadly accepted recommendation to administer prophylaxis within a 60-minute time frame prior to incision could not be substantiated.

FULL TEXT

http://journals.lww.com/md-journal/Fulltext/2017/07210/Timing_of_preoperative_antibiotic_prophylaxis_in.1.aspx

PDF CLIC en “Article as PDF” (download)

July 22, 2017 at 10:01 am

The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis.

Ann Clin Microbiol Antimicrob. April 5, 2017 V.16 N.1 P.24.     

Wang J1, Pan Y1, Shen J2, Xu Y1.

Author information

1 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, Anhui, China.

2 Department of Clinical Laboratory, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, 230022, Anhui, China. shenjilu@126.com

Abstract

Patients with bloodstream infections (BSI) are associated with high mortality rates. Due to tigecycline has shown excellent in vitro activity against most pathogens, tigecycline is selected as one of the candidate drugs for the treatment of multidrug-resistant organisms infections.

The purpose of this study was to evaluate the effectiveness and safety of the use of tigecycline for the treatment of patients with BSI. The PubMed and Embase databases were systematically searched, to identify published studies, and we searched clinical trial registries to identify completed unpublished studies, the results of which were obtained through the manufacturer.

The primary outcome was mortality, and the secondary outcomes were the rate of clinical cure and microbiological success. 24 controlled studies were included in this systematic review. All-cause mortality was lower with tigecycline than with control antibiotic agents, but the difference was not significant (OR 0.85, [95% confidence interval (CI) 0.31-2.33; P = 0.745]). Clinical cure was significantly higher with tigecycline groups (OR 1.76, [95% CI 1.26-2.45; P = 0.001]).

Eradication efficiency did not differ between tigecycline and control regimens, but the sample size for these comparisons was small. Subgroup analyses showed good clinical cure result in bacteremia patients with CAP. Tigecycline monotherapy was associated with a OR of 2.73 (95% CI 1.53-4.87) for mortality compared with tigecycline combination therapy (6 studies; 250 patients), without heterogeneity.

Five studies reporting on 398 patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae BSI showed significantly lower mortality in the tigecycline arm than in the control arm. The combined treatment with tigecycline may be considered the optimal option for severely ill patients with BSI.

PDF

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382384/pdf/12941_2017_Article_199.pdf

July 2, 2017 at 9:31 pm

Prevalence of multidrug-resistant gram-negative bacteria among nursing home residents: A systematic review and meta-analysis.

American Journal of Infection Control May 1, 2017 V.45 N.5 P.512-518

Sainfer Aliyu, MPhil, MSEd, MHPM, BSN, RN’MPhil, MSEd, MHPM, BSN, RN Sainfer Aliyu, MSEd, MHPM, BSN, RN Sainfer Aliyu, Arlene Smaldone, PhD, CPNP, CDE, Elaine Larson, PhD, RN, CIC, FAAN

Highlights

  • Multidrug resistant-gram negative bacteria colonization ranged from 11.2%-59.1%.
  • E coli accounted for the largest proportion of isolates.
  • The most common site of colonization was rectal, followed by nasal, sputum, urinary tract and wound.
  • Colonization was significantly higher in studies conducted in United States (38%) compared to other countries (14%).

Background

Multidrug-resistant gram-negative bacteria (MDR-GNB) are associated with an increasing proportion of infections among nursing home (NH) residents. The objective of this systematic review and meta-analysis was to critically review evidence of the prevalence of MDR-GNB among NH residents.

Methods

Following Meta-Analysis of Observational Studies in Epidemiology guidelines, a systematic review of literature for the years 2005-2016 using multiple databases was conducted. Study quality, appraised by 2 reviewers, used Downs and Black risk of bias criteria. Studies reporting prevalence of MDR-GNB colonization were pooled using a random effects meta-analysis model. Heterogeneity was assessed using Cochran Q and I2 statistics.

Results

Of 327 articles, 12 met the criteria for review; of these, 8 met the criteria for meta-analysis. Escherichia coli accounted for the largest proportion of isolates. Reported MDR-GNB colonization prevalence ranged from 11.2%-59.1%. Pooled prevalence for MDR-GNB colonization, representing data from 2,720 NH residents, was 27% (95% confidence interval, 15.2%-44.1%) with heterogeneity (Q = 405.6; P = .01; I2 = 98.3). Two studies reported MDR-GNB infection rates of 10.9% and 62.7%.

Conclusion

Our findings suggest a high prevalence of MDR-GNB colonization among NH residents, emphasizing the need to enhance policies for infection control and prevention (ICP) in NHs.

FULL TEXT

http://www.ajicjournal.org/article/S0196-6553(17)30085-8/fulltext

PDF

http://www.ajicjournal.org/article/S0196-6553(17)30085-8/pdf

 

June 9, 2017 at 8:08 am

Older Posts


Calendar

November 2017
M T W T F S S
« Oct    
 12345
6789101112
13141516171819
20212223242526
27282930  

Posts by Month

Posts by Category